Revance Therapeutics Statistics
Share Statistics
Revance Therapeutics has 104.39M shares outstanding. The number of shares has increased by 18.64% in one year.
| Shares Outstanding | 104.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.26% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 95.30M |
| Failed to Deliver (FTD) Shares | 1.04K |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 10.00M, so 9.54% of the outstanding shares have been sold short.
| Short Interest | 10.00M |
| Short % of Shares Out | 9.54% |
| Short % of Float | 10.45% |
| Short Ratio (days to cover) | 6.06 |
Valuation Ratios
The PE ratio is -2.3 and the forward PE ratio is -4.33.
| PE Ratio | -2.3 |
| Forward PE | -4.33 |
| PS Ratio | 3.18 |
| Forward PS | 0.9 |
| PB Ratio | -4.91 |
| P/FCF Ratio | -3.33 |
| PEG Ratio | n/a |
Enterprise Valuation
Revance Therapeutics Inc. has an Enterprise Value (EV) of 1.08B.
| EV / Earnings | -3.35 |
| EV / Sales | 4.63 |
| EV / EBITDA | -3.73 |
| EV / EBIT | -3.42 |
| EV / FCF | -4.85 |
Financial Position
The company has a current ratio of 3.8, with a Debt / Equity ratio of -2.83.
| Current Ratio | 3.8 |
| Quick Ratio | 3.29 |
| Debt / Equity | -2.83 |
| Total Debt / Capitalization | 154.63 |
| Cash Flow / Debt | -0.5 |
| Interest Coverage | -16.37 |
Financial Efficiency
Return on equity (ROE) is 2.14% and return on capital (ROIC) is -97.01%.
| Return on Equity (ROE) | 2.14% |
| Return on Assets (ROA) | -0.68% |
| Return on Capital (ROIC) | -97.01% |
| Revenue Per Employee | 392.03K |
| Profits Per Employee | -542.69K |
| Employee Count | 597 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.34 |
Taxes
| Income Tax | 300.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -61.88% in the last 52 weeks. The beta is 0.95, so Revance Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -61.88% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 4.45 |
| Relative Strength Index (RSI) | 32.67 |
| Average Volume (20 Days) | 3.05M |
Income Statement
In the last 12 months, Revance Therapeutics had revenue of $234.04M and earned -$323.99M in profits. Earnings per share was $-3.83.
| Revenue | 234.04M |
| Gross Profit | 81.88M |
| Operating Income | -316.78M |
| Net Income | -323.99M |
| EBITDA | -290.64M |
| EBIT | -316.78M |
| Earnings Per Share (EPS) | -3.83 |
Balance Sheet
The company has $137.33M in cash and $478.43M in debt, giving a net cash position of -$341.11M.
| Cash & Cash Equivalents | 137.33M |
| Total Debt | 478.43M |
| Net Cash | -341.11M |
| Retained Earnings | -2.08B |
| Total Assets | 461.56M |
| Working Capital | 249.64M |
Cash Flow
In the last 12 months, operating cash flow was -$216.57M and capital expenditures -$6.89M, giving a free cash flow of -$223.46M.
| Operating Cash Flow | -216.57M |
| Capital Expenditures | -6.89M |
| Free Cash Flow | -223.46M |
| FCF Per Share | -2.64 |
Margins
Gross margin is 34.98%, with operating and profit margins of -135.35% and -138.43%.
| Gross Margin | 34.98% |
| Operating Margin | -135.35% |
| Pretax Margin | -138.3% |
| Profit Margin | -138.43% |
| EBITDA Margin | -124.18% |
| EBIT Margin | -135.35% |
| FCF Margin | -95.48% |
Dividends & Yields
RVNC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -124.35% |
| FCF Yield | -69.39% |
Analyst Forecast
The average price target for RVNC is $6.8, which is 120.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.8 |
| Price Target Difference | 120.8% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
Scores
| Altman Z-Score | -6.32 |
| Piotroski F-Score | 3 |